268 related articles for article (PubMed ID: 34649118)
1. Baseline co-medications may alter the anti-tumoural effect of checkpoint inhibitors as well as the risk of immune-related adverse events.
Kostine M; Mauric E; Tison A; Barnetche T; Barre A; Nikolski M; Rouxel L; Dutriaux C; Dousset L; Prey S; Beylot-Barry M; Seneschal J; Veillon R; Vergnenegre C; Daste A; Domblides C; Sionneau B; Gross-Goupil M; Ravaud A; Forcade E; Schaeverbeke T;
Eur J Cancer; 2021 Nov; 157():474-484. PubMed ID: 34649118
[TBL] [Abstract][Full Text] [Related]
2. Integrated analysis of concomitant medications and oncological outcomes from PD-1/PD-L1 checkpoint inhibitors in clinical practice.
Cortellini A; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Bisonni R; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Marconcini R; Vitale MG; Nicolardi L; Chiari R; Bareggi C; Nigro O; Tuzi A; De Tursi M; Petragnani N; Pala L; Bracarda S; Macrini S; Inno A; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Pinato DJ; Porzio G; Ficorella C; Ascierto PA
J Immunother Cancer; 2020 Nov; 8(2):. PubMed ID: 33154150
[TBL] [Abstract][Full Text] [Related]
3. Impact of antibiotic use and other concomitant medications on the efficacy of immune checkpoint inhibitors in patients with advanced cancer.
Iglesias-Santamaría A
Clin Transl Oncol; 2020 Sep; 22(9):1481-1490. PubMed ID: 31919759
[TBL] [Abstract][Full Text] [Related]
4. Impact of Antibiotics and Proton Pump Inhibitors on Efficacy and Tolerance of Anti-PD-1 Immune Checkpoint Inhibitors.
Giordan Q; Salleron J; Vallance C; Moriana C; Clement-Duchene C
Front Immunol; 2021; 12():716317. PubMed ID: 34777340
[TBL] [Abstract][Full Text] [Related]
5. Impact of concurrent medications on clinical outcomes of cancer patients treated with immune checkpoint inhibitors: analysis of Health Insurance Review and Assessment data.
Hong S; Lee JH; Heo JY; Suh KJ; Kim SH; Kim YJ; Kim JH
J Cancer Res Clin Oncol; 2024 Apr; 150(4):186. PubMed ID: 38600328
[TBL] [Abstract][Full Text] [Related]
6. Associations of concomitant medications with immune-related adverse events and survival in advanced cancers treated with immune checkpoint inhibitors: a comprehensive pan-cancer analysis.
Nara K; Taguchi S; Buti S; Kawai T; Uemura Y; Yamamoto T; Kume H; Takada T
J Immunother Cancer; 2024 Mar; 12(3):. PubMed ID: 38458634
[TBL] [Abstract][Full Text] [Related]
7. Incidence and risk factors of acute kidney injury in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis.
Liu C; Wei W; Yang L; Li J; Yi C; Pu Y; Yin T; Na F; Zhang L; Fu P; Zhao Y
Front Immunol; 2023; 14():1173952. PubMed ID: 37313406
[TBL] [Abstract][Full Text] [Related]
8. The effects of antibiotics on the efficacy of immune checkpoint inhibitors in patients with non-small-cell lung cancer differ based on PD-L1 expression.
Ochi N; Ichihara E; Takigawa N; Harada D; Inoue K; Shibayama T; Hosokawa S; Kishino D; Harita S; Oda N; Hara N; Hotta K; Maeda Y; Kiura K
Eur J Cancer; 2021 May; 149():73-81. PubMed ID: 33838391
[TBL] [Abstract][Full Text] [Related]
9. Risk factors of immune checkpoint inhibitor-associated acute kidney injury: evidence from clinical studies and FDA pharmacovigilance database.
Chen P; Zhu J; Xu Y; Huang Q; Su J; Gao Z; Feng M
BMC Nephrol; 2023 Apr; 24(1):107. PubMed ID: 37087434
[TBL] [Abstract][Full Text] [Related]
10. Effect of concomitant medications with immune-modulatory properties on the outcomes of patients with advanced cancer treated with immune checkpoint inhibitors: development and validation of a novel prognostic index.
Buti S; Bersanelli M; Perrone F; Tiseo M; Tucci M; Adamo V; Stucci LS; Russo A; Tanda ET; Spagnolo F; Rastelli F; Pergolesi F; Santini D; Russano M; Anesi C; Giusti R; Filetti M; Marchetti P; Botticelli A; Gelibter A; Occhipinti MA; Ferrari M; Vitale MG; Nicolardi L; Chiari R; Rijavec E; Nigro O; Tuzi A; De Tursi M; Di Marino P; Conforti F; Queirolo P; Bracarda S; Macrini S; Gori S; Zoratto F; Veltri E; Di Cocco B; Mallardo D; Vitale MG; Santoni M; Patruno L; Porzio G; Ficorella C; Pinato DJ; Ascierto PA; Cortellini A
Eur J Cancer; 2021 Jan; 142():18-28. PubMed ID: 33212418
[TBL] [Abstract][Full Text] [Related]
11. Role of the gut microbiome for cancer patients receiving immunotherapy: Dietary and treatment implications.
Lee KA; Shaw HM; Bataille V; Nathan P; Spector TD
Eur J Cancer; 2020 Oct; 138():149-155. PubMed ID: 32889369
[TBL] [Abstract][Full Text] [Related]
12. Clinical impact of proton pump inhibitors and other co-medications on advanced melanoma patients treated with BRAF/MEK inhibitors.
Ramel E; Prey S; Dutriaux C; Gerard E; Pham-Ledard A; Beylot-Barry M; Kostine M
Eur J Cancer; 2024 Jan; 197():113477. PubMed ID: 38113780
[TBL] [Abstract][Full Text] [Related]
13. Angiotensin-converting enzyme (ACE) inhibitor prescription affects non-small-cell lung cancer (NSCLC) patients response to PD-1/PD-L1 immune checkpoint blockers.
Medjebar S; Truntzer C; Perrichet A; Limagne E; Fumet JD; Richard C; Elkrief A; Routy B; Rébé C; Ghiringhelli F
Oncoimmunology; 2020 Oct; 9(1):1836766. PubMed ID: 33178495
[TBL] [Abstract][Full Text] [Related]
14. Conditional immune toxicity rate in patients with metastatic renal and urothelial cancer treated with immune checkpoint inhibitors.
Nuzzo PV; Pond GR; Abou Alaiwi S; Nassar AH; Flippot R; Curran C; Kilbridge KL; Wei XX; McGregor BA; Choueiri T; Harshman LC; Sonpavde G
J Immunother Cancer; 2020 Mar; 8(1):. PubMed ID: 32234849
[TBL] [Abstract][Full Text] [Related]
15. Role of the intestinal microbiome and microbial-derived metabolites in immune checkpoint blockade immunotherapy of cancer.
Hayase E; Jenq RR
Genome Med; 2021 Jun; 13(1):107. PubMed ID: 34162429
[TBL] [Abstract][Full Text] [Related]
16. Concomitant Medication Effects on Immune Checkpoint Inhibitor Efficacy and Toxicity.
Sieber B; Strauss J; Li Z; Gatti-Mays ME
Front Oncol; 2022; 12():836934. PubMed ID: 35712518
[TBL] [Abstract][Full Text] [Related]
17. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
[TBL] [Abstract][Full Text] [Related]
18. Inferring the role of the microbiome on survival in patients treated with immune checkpoint inhibitors: causal modeling, timing, and classes of concomitant medications.
Spakowicz D; Hoyd R; Muniak M; Husain M; Bassett JS; Wang L; Tinoco G; Patel SH; Burkart J; Miah A; Li M; Johns A; Grogan M; Carbone DP; Verschraegen CF; Kendra KL; Otterson GA; Li L; Presley CJ; Owen DH
BMC Cancer; 2020 May; 20(1):383. PubMed ID: 32375706
[TBL] [Abstract][Full Text] [Related]
19. Clinical characteristics of gastrointestinal immune-related adverse events of immune checkpoint inhibitors and their association with survival.
Yamada K; Sawada T; Nakamura M; Yamamura T; Maeda K; Ishikawa E; Iida T; Mizutani Y; Kakushima N; Ishikawa T; Furukawa K; Ohno E; Honda T; Kawashima H; Ishigami M; Furune S; Hase T; Yokota K; Maeda O; Hashimoto N; Akiyama M; Ando Y; Fujishiro M
World J Gastroenterol; 2021 Nov; 27(41):7190-7206. PubMed ID: 34887637
[TBL] [Abstract][Full Text] [Related]
20. Association of prior fluoroquinolone treatment with survival outcomes of immune checkpoint inhibitors in Asia.
Lu PH; Tsai TC; Chang JW; Deng ST; Cheng CY
J Clin Pharm Ther; 2021 Apr; 46(2):408-414. PubMed ID: 33332621
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
